Pemetrexed in the treatment of selected solid tumors.

Article Details

Citation

Copy to clipboard

Adjei AA

Pemetrexed in the treatment of selected solid tumors.

Semin Oncol. 2002 Apr;29(2 Suppl 5):50-3.

PubMed ID

12023793 [ View in PubMed

]

Abstract

The novel agent pemetrexed inhibits thymidylate synthase, dihydrofolate reductase, and glycinamide ribonucleotide formyltransferase. Significant activity has been seen in completed phase II trials of pemetrexed in non-small cell lung cancer and breast cancer. Pemetrexed is also active in combination with other agents such as gemcitabine, cisplatin, and carboplatin. In addition, this agent shows promising activity in bladder, head and neck, esophageal, renal, and cervical carcinomas. Preliminary results of studies in these tumor types are reviewed.

DrugBank Data that Cites this Article

Drug Targets

Drug	Target	Kind	Organism	Pharmacological Action	Actions
Pemetrexed	Dihydrofolate reductase	Protein	Humans	Yes	Inhibitor	Details
Pemetrexed	Thymidylate synthase	Protein	Humans	Yes	Inhibitor	Details
Pemetrexed	Trifunctional purine biosynthetic protein adenosine-3	Protein	Humans	Yes	Inhibitor	Details